BCAX
insider transactionsBicara Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+1.9M
2.5M buy · 551.0K sell
Net value · 365d
$29.8M
$40.0M in · $10.2M out
Sentiment · 365d
Net buying
80% buying · 20% selling
Open-market trades · 365d
61
2.5M buy · 551.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 365d
-
Buy·P
Director,TenPercentOwner
$35.2M
2.2M sh · $16.00
Own New
-
Buy·P
Director,TenPercentOwner
$4.8M
300.0K sh · $16.00
Own +7%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 26, 2026 | RA CAPITAL MANAGEMENT, L.P. | Buy P | 2.2M | $35.2M |
| Feb 26, 2026 | RA CAPITAL MANAGEMENT, L.P. | Buy P | 300.0K | $4.8M |
Buy Sell Non-market (grant · exercise · gift)
About BCAX insider trading
This page tracks insider transactions for Bicara Therapeutics Inc. (BCAX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.